Compound Evidence File
#EC-2026-0437
5-amino-1MQ Oral
Filed under Oral Tablets. The bureau holds 117 laboratory returns for this compound from 36 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
36 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 10.0 | 10.0 | 15 Jan 2026 | 6 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Nov 2025 | 20 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 22 Feb 2026 | 22 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 20 Feb 2026 | 17 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 14 Mar 2026 | 22 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 10.0 | 10.0 | 22 Mar 2026 | 10 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 10.0 | 10.0 | 22 Feb 2026 | 6 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 10.0 | 10.0 | 3 Apr 2026 | 17 Jul 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 10.0 | 10.0 | 10.0 | 21 May 2026 | 21 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 8 Dec 2025 | 18 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Jun 2026 | 11 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 10 May 2026 | 7 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Apr 2026 | 4 May 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 8 Mar 2026 | 19 Apr 2026 |
| Atomik LabzCASE #VI-2026-0327 | X | 1 | 10.0 | 10.0 | 10.0 | 21 May 2025 | 21 May 2025 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 9.9 | 2 Nov 2025 | 28 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 4 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 4 Jan 2026 | 24 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 28 May 2026 | 11 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Jul 2026 | 20 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 18 May 2026 | 17 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Feb 2026 | 26 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 2 May 2026 | 9 Aug 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 9.5 | 9.5 | 9.5 | 25 Apr 2025 | 25 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 9.1 | 8.4 | 9.7 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.9 | 7.9 | 9.8 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.5 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.5 | 8.1 | 8.9 | 21 May 2026 | 21 May 2026 |
| HXNetCASE #VI-2026-0061 | X | 8 | 7.0 | 4.8 | 9.6 | 25 Apr 2025 | 23 May 2026 |
| Forever Young PharmacyCASE #VI-2026-0654 | X | 2 | 6.5 | 4.7 | 8.3 | 16 Mar 2025 | 26 Jan 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 10 | 5.9 | 3.6 | 8.6 | 9 Jun 2025 | 21 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 5.9 | 5.9 | 5.9 | 3 Jun 2025 | 3 Jun 2025 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 5.2 | 4.6 | 5.8 | 9 Jun 2025 | 19 Jan 2026 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.9 | 0.9 | 0.9 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for 5-amino-1MQ Oral alone.